OGNOrganon & Co.
What is the market doing?
No clear lean: nothing decisive, though in an uptrend.
In an uptrend, above its rising 50- and 200-day averages. Price is +30% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 5.0% since the previous count, down from 7.2% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How OGN is trading
Organon & Co. is +33% over the past year while the S&P 500 is +18%: 15 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +30%
vs 200-day average · a clear uptrend
- RSI (14)
- 69
RSI (14) · neutral
- Below its 52-week high
- 0.00%
Below its 52-week high
Details›
- Last close2026-10-09
- $13.81
- 1 monthS&P 500 +2.7%
- +1.2%
- 1 yearS&P 500 +18%
- +33%
- 5 yearsS&P 500 +88%
- −50%
- vs 50-day average$13.70
- +0.79%
- 52-week high
- $13.80
- 52-week low
- $5.69
- Annualised volatility
- 60%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$553K
| Year | Return |
|---|---|
| 2026 (year to date) | +93% |
| 2025 | −51% |
| 2024 | +9.9% |
| 2023 | −45% |
| 2022 | −4.9% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 5 | 5 of 5 | +10% |
| Feb | 5 | 2 of 5 | −2.1% |
| Mar | 5 | 1 of 5 | −4.1% |
| Apr | 5 | 2 of 5 | +21% |
| May | 5 | 3 of 5 | −2.7% |
| Jun | 6 | 3 of 6 | −2.7% |
| Jul | 6 | 4 of 6 | +0.28% |
| Aug | 6 | 4 of 6 | +2.1% |
| Sep | 6 | 1 of 6 | −7.3% |
| Oct | 6 | 3 of 6 | −4.8% |
| Nov | 5 | 2 of 5 | −8.0% |
| Dec | 5 | 3 of 5 | +5.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, General
Ranks #4 of 7 by RyuScore